Pacer Advisors Inc. increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 13.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,345 shares of the medical instruments supplier’s stock after acquiring an additional 1,110 shares during the period. Pacer Advisors Inc.’s holdings in DENTSPLY SIRONA were worth $559,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of XRAY. Shell Asset Management Co. boosted its holdings in shares of DENTSPLY SIRONA by 16.1% in the second quarter. Shell Asset Management Co. now owns 17,699 shares of the medical instruments supplier’s stock valued at $1,148,000 after acquiring an additional 2,450 shares in the last quarter. NGAM Advisors L.P. boosted its holdings in shares of DENTSPLY SIRONA by 1.5% in the second quarter. NGAM Advisors L.P. now owns 100,151 shares of the medical instruments supplier’s stock valued at $6,493,000 after acquiring an additional 1,489 shares in the last quarter. IBM Retirement Fund boosted its holdings in shares of DENTSPLY SIRONA by 29.9% in the second quarter. IBM Retirement Fund now owns 3,324 shares of the medical instruments supplier’s stock valued at $216,000 after acquiring an additional 766 shares in the last quarter. Harbour Capital Advisors LLC boosted its holdings in shares of DENTSPLY SIRONA by 6,384.0% in the second quarter. Harbour Capital Advisors LLC now owns 42,146 shares of the medical instruments supplier’s stock valued at $650,000 after acquiring an additional 41,496 shares in the last quarter. Finally, Warren Averett Asset Management LLC bought a new position in shares of DENTSPLY SIRONA in the second quarter valued at approximately $248,000. Institutional investors and hedge funds own 96.59% of the company’s stock.

In other news, insider Mark Thierer acquired 77,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $66.04 per share, with a total value of $5,085,080.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. Company insiders own 1.99% of the company’s stock.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) opened at $66.08 on Friday. The firm has a market cap of $15,391.05, a P/E ratio of 26.70, a P/E/G ratio of 2.65 and a beta of 1.31. DENTSPLY SIRONA Inc. has a 1-year low of $52.53 and a 1-year high of $68.98. The company has a current ratio of 2.32, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $0.66 earnings per share. equities research analysts predict that DENTSPLY SIRONA Inc. will post 2.66 EPS for the current fiscal year.

Several research firms have recently issued reports on XRAY. HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective (down from $74.00) on shares of DENTSPLY SIRONA in a report on Monday, August 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $66.00 price objective (down from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. UBS reiterated a “neutral” rating and issued a $59.00 price objective (down from $62.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Stephens began coverage on shares of DENTSPLY SIRONA in a report on Tuesday. They issued an “overweight” rating and a $75.00 price objective for the company. Finally, TheStreet cut shares of DENTSPLY SIRONA from a “b” rating to a “c+” rating in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. DENTSPLY SIRONA has a consensus rating of “Hold” and an average price target of $67.73.

COPYRIGHT VIOLATION NOTICE: “DENTSPLY SIRONA Inc. (XRAY) Stake Lifted by Pacer Advisors Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/dentsply-sirona-inc-xray-stake-lifted-by-pacer-advisors-inc/1738815.html.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.